S
NBIX icon

Seeyond’s Neurocrine Biosciences NBIX Stock Holding History

Seeyond’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.45M Sell
20,524
-3,003
-13% -$352K 0.24% 140
2022
Q3 		$2.5M Buy
23,527
+764
+3% +$77.5K 0.3% 90
2022
Q2 		$2.22M Buy
22,763
+3,910
+21% +$361K 0.25% 100
2022
Q1 		$1.77M Buy
18,853
+7,896
+72% +$669K 0.18% 192
2021
Q4 		$933K Hold
10,957
– – 0.09% 376
2021
Q3 		$1.05M Sell
10,957
-111
-1% -$10.5K 0.1% 324
2021
Q2 		$1.08M Buy
11,068
+50
+0.5% +$4.79K 0.1% 307
2021
Q1 		$1.07M Sell
11,018
-26,431
-71% -$2.77M 0.11% 296
2020
Q4 		$3.59M Sell
37,449
-12,373
-25% -$1.2M 0.37% 40
2020
Q3 		$4.79M Sell
49,822
-7,856
-14% -$909K 0.52% 30
2020
Q2 		$7.04M Buy
57,678
+53,232
+1,197% +$5.88M 0.8% 19
2020
Q1 		$128K Sell
4,446
-35
-0.8% -$3.42K 0.02% 538
2019
Q4 		$219K Buy
+4,481
New +$469K 0.02% 535

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Seeyond's NBIX Position: Q4 2022 in Review

Seeyond reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q4 2022, selling an estimated $352K and leaving 20,524 shares worth $2.45M. The position accounts for 0.24% of the portfolio, ranked #140.

Seeyond first reported a position in NBIX in Q4 2019 and has held it in 13 quarters since. The position peaked at $7.04M in Q2 2020. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Seeyond held 20,524 shares of Neurocrine Biosciences worth $2.45M as of Q4 2022.
  • Seeyond sold 3,003 Neurocrine Biosciences shares in Q4 2022, an estimated $352K.
  • Neurocrine Biosciences made up 0.24% of Seeyond's portfolio in Q4 2022, its #140 holding.
  • Seeyond first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 13 quarters since.
  • Seeyond's Neurocrine Biosciences position peaked at $7.04M in Q2 2020.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Seeyond's 13F filing for Q4 2022, filed 13 Feb 2023.